SCHEMBL29610472

SCHEMBL29610472

O=C1CCC(N2C(=O)c3ccc(C4(F)CCN(Cc5ccccc5)CC4)c4cccc2c34)C(=O)N1

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
IKZF2 Q9UKS7 4/20 0.49
CRBN Q96SW2 13/20 0.44
IKZF3 Q9UKT9 7/20 0.44
DDB1 Q16531 10/20 0.43
BCL2L11 O43521 1/20 0.43
BCL2 P10415 1/20 0.43
MCL1 Q07820 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CHRM2 P08172 1/20 0.43
OPRM1 P35372 1/20 0.43
CYP1A2 P05177 1/20 0.43
TSHR P16473 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
IKZF1 Q13422 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24315937 1.00 IKZF2 (0.49) IKZF2CRBNIKZF3DDB1BCL2L11
SCHEMBL24315781 0.91 IKZF2 (0.46) IKZF2CRBNIKZF3DDB1BCL2L11
SCHEMBL29610400 0.91 IKZF2 (0.46) IKZF2CRBNIKZF3DDB1BCL2L11
SCHEMBL24315835 0.90 IKZF2 (0.49) IKZF2CRBNIKZF3DDB1BCL2L11
SCHEMBL29611029 0.87 CRBN (0.48) CRBNIKZF3DDB1BCL2L11BCL2
SCHEMBL24315939 0.87 CRBN (0.48) CRBNIKZF3DDB1BCL2L11BCL2
SCHEMBL29610888 0.86 IKZF2 (0.60) IKZF2CRBNIKZF3DDB1BCL2L11
SCHEMBL24315904 0.86 IKZF2 (0.60) IKZF2CRBNIKZF3DDB1BCL2L11
SCHEMBL24315922 0.86 IKZF2 (0.46) IKZF2CRBNIKZF3DDB1ALDH1A1
SCHEMBL26648211 0.84 IKZF2 (0.46) IKZF2CRBNIKZF3DDB1BCL2L11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4228639-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 Therapeutics, Inc. (US) 2023-08-23 EP disclosed
WO-2022081925-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed